Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG (MelanooMSOT)
Primary Purpose
Melanoma, Stage I, Melanoma, Stage II, Melanoma Stage III
Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
MSOT
Sponsored by

About this trial
This is an interventional diagnostic trial for Melanoma, Stage I
Eligibility Criteria
Inclusion Criteria:
- Patients with grade Ib- III melanoma scheduled for SLNB and/or surgical excision.
- Patients must be > 18 years old and be able to give informed consent.
- Skintype I-IV following Fitzpatrick skin classification (MSOT less reliable in skin types >IV)
Exclusion Criteria:
- Apparent hyperthyroidism or autonomous thyroid adenoma of the thyroid gland
- Prior surgery or radiotherapy on involved lymph nodes / area
- Major surgery within 28 days before tracer administration
- Pregnant or nursing women, fertile women will need a negative pregnancy test prior to inclusion
- History of iodine allergy or anaphylactic reactions to insect bites
- Hypersensitivity to ICG or poorly tolerated ICG in the past
- Unexplained allergic reaction in the past
- Skin type >IV following Fitzpatrick skin classification (MSOT less reliable)
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Standard of care + MSOT
Arm Description
Standard of care + MSOT
Outcomes
Primary Outcome Measures
Concordance rate of SLNs identified by MSOT imaging and ICG versus the standard of care with 99mTc-nanocolloid Tc99m and lymphoscintigraphic imaging
Secondary Outcome Measures
Patient characteristics
Age, sex, BMI, history and morbidity, localization and extent of primary tumor, baseline blood count/liver and kidney function
Full Information
NCT ID
NCT05467137
First Posted
July 1, 2022
Last Updated
July 15, 2022
Sponsor
University Medical Center Groningen
1. Study Identification
Unique Protocol Identification Number
NCT05467137
Brief Title
Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG
Acronym
MelanooMSOT
Official Title
Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MultiSpectral Optoacoustic Tomography (MSOT) and IndoCyanine Green (ICG)
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 2022 (Anticipated)
Primary Completion Date
November 2022 (Anticipated)
Study Completion Date
March 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Medical Center Groningen
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In this study the investigators try to identify the sentinel lymph node in patients with stage Ib-III melanoma in a non-invasive manner without the use of a radioactive tracer by using the new MSOT technology.
Detailed Description
Over the past few decades, melanoma has been one of the fastest-growing cancers and the incidence rate of melanoma is still increasing. Standard treatment for melanoma is wide (re)excision. Sentinel lymph node (SLN) biopsy (SLNB) is recommended for patients with melanoma of AJCC stage pT1b or higher according to Dutch guidelines. SLNB provides essential staging information that impacts on the clinical management of patients with melanoma, and the presence of SLN metastasis indicates a significantly worse prognosis. However, the overall complication rate of SLNB is high.
Currently, lymphoscintigraphy using 99mTc-nanocolloid Technetium-99m-nanocolloïd (Tc99m) is the gold standard to identify the sentinel lymph node. However, there are various disadvantages of using 99mTc-nanocolloidTc99m: the involvement of radioisotopes represents a radioactive burden for patients and caregivers, the lymphoscintigraphic imaging has poor spatial resolution, and the involvement of radioisotopes is expensive and creates logistic challenges. Therefore, in this study the goal is to identify the sentinel lymph node in a non-invasive manner without the use of a radioactive tracer. The investigators try to reach this goal by using the fluorophore dye IndoCyanine Green (ICG) and multispectral optoacoustic imaging (MSOT).
MSOT is a new, but increasingly used, imaging modality that has emerged the field of optical imaging. MSOT is based on a highly powerful pulsed laser in different wavelengths. Photo absorbing molecules absorb laser light in a specific wavelength, undergo thermal expansion and create soundwaves which can be detected by special transducers. The MSOT combines conventional ultrasonography with optoacoustic imaging which gives both anatomical and biological information and is currently available in the University Medical Centre Groningen (UMCG).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Melanoma, Stage I, Melanoma, Stage II, Melanoma Stage III
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Standard of care + MSOT
Arm Type
Experimental
Arm Description
Standard of care + MSOT
Intervention Type
Device
Intervention Name(s)
MSOT
Intervention Description
MSOT imaging (after ICG injection)
Primary Outcome Measure Information:
Title
Concordance rate of SLNs identified by MSOT imaging and ICG versus the standard of care with 99mTc-nanocolloid Tc99m and lymphoscintigraphic imaging
Time Frame
Through study completion (an average of 1 year)
Secondary Outcome Measure Information:
Title
Patient characteristics
Description
Age, sex, BMI, history and morbidity, localization and extent of primary tumor, baseline blood count/liver and kidney function
Time Frame
Through study completion (an average of 1 year)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with grade Ib- III melanoma scheduled for SLNB and/or surgical excision.
Patients must be > 18 years old and be able to give informed consent.
Skintype I-IV following Fitzpatrick skin classification (MSOT less reliable in skin types >IV)
Exclusion Criteria:
Apparent hyperthyroidism or autonomous thyroid adenoma of the thyroid gland
Prior surgery or radiotherapy on involved lymph nodes / area
Major surgery within 28 days before tracer administration
Pregnant or nursing women, fertile women will need a negative pregnancy test prior to inclusion
History of iodine allergy or anaphylactic reactions to insect bites
Hypersensitivity to ICG or poorly tolerated ICG in the past
Unexplained allergic reaction in the past
Skin type >IV following Fitzpatrick skin classification (MSOT less reliable)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jutten
Phone
0031 50 361 6161
Email
e.jutten@umcg.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
van Leeuwen
Organizational Affiliation
University Medical Center Groningen
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG
We'll reach out to this number within 24 hrs